Funded Startups in Labège
The largest disclosed round in Labège is Donecle’s $12M (Series Unknown) on 2026-04-15, and it sits near the lower end of the disclosed range: four of the…
The largest disclosed round in Labège is Donecle’s $12M (Series Unknown) on 2026-04-15, and it sits near the lower end of the disclosed range: four of the six entries are at or above $12M, while Antabio’s $27M (2023-12-12) and EyeLights’ $22M (2023-04-12) are the standout higher amounts, and Declique’s $300K (2020-11-17) is the major low outlier.
The six most recent rounds shown are tightly clustered by geography (all list Labège, Midi-Pyrenees, France) and by time: three rounds fall between 2023-04-12 and 2023-12-12 (EyeLights $22M, MerciYanis $3M, Antabio $27M). Sector mix skews toward consumer/tech-adjacent categories (Consumer Electronics appears twice: Donecle 2026-04-15 $12M and EyeLights 2023-04-12 $22M), and stage labels are uneven, with one row leaving the series blank (Declique) and one explicitly marked “Series Unknown” (Donecle). The range spans 2020-11-17 to 2026-04-15 (oldest to most recent in the table).
Most recent rounds
6 shownRelated listings
Frequently asked
Which round is the largest in Labège among the six most recent entries, and how does it compare with the rest?
Antabio’s $27M (Series B, 2023-12-12) is the largest disclosed amount, and it’s notably above the next-largest disclosed rounds: EyeLights’ $22M (2023-04-12) and Alteia’s $17M (Debt Financing, 2021-12-01). Declique’s $300K (2020-11-17) is the low outlier.
Are the Labège rounds clustered into a specific time window?
Yes. Three of the six disclosed rounds land within 2023 (EyeLights $22M on 2023-04-12, MerciYanis $3M on 2023-10-12, and Antabio $27M on 2023-12-12). The earlier and later entries bookend that period with Declique in 2020-11-17 ($300K) and Donecle in 2026-04-15 ($12M).
Does any sector show up repeatedly in this Labège list?
Consumer Electronics appears twice: Donecle (2026-04-15, $12M, Series Unknown) and EyeLights (2023-04-12, $22M, Series A). The remaining sectors each appear once (Biotechnology, Internet Services, AI, and Information Technology).
What stage labels dominate, and how much of the table is missing or ambiguous?
Series A appears twice (MerciYanis $3M on 2023-10-12 and EyeLights $22M on 2023-04-12). The remaining rows are split across Series B (Antabio $27M, 2023-12-12), Debt Financing (Alteia $17M, 2021-12-01), one “Series Unknown” (Donecle $12M, 2026-04-15), and one blank series field (Declique $300K, 2020-11-17).
Which entries look like outliers by amount rather than by timing or sector?
Declique’s $300K on 2020-11-17 is the clear low outlier versus all other disclosed amounts ($3M, $12M, $17M, $22M, and $27M). At the high end, Antabio’s $27M on 2023-12-12 is the top figure, sitting above EyeLights’ $22M (2023-04-12) and Alteia’s $17M (2021-12-01).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.